Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating

Benzinga Newsdesk www.benzinga.com Neutral 75.8%

Neg 0% Neu 75.8% Pos 0%

Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Overweight rating.